Search PubMed⌕ Search

Biomedical subjects

T Francuz

Publications and source records attributed to T Francuz.

4 recordsLinked to original sources

Activity of antioxidant enzymes in children from families at high risk of premature coronary heart disease.

A positive family history of coronary heart disease (CHD) is one of the most predictive risk factors of CHD. Many children with increased risk of CHD because of their positive family history of CHD do not present other risk factors, such as altered serum lipid profile. Oxidative stress plays an important part in the pathogenesis of atherosclerosis. Serum antioxidants and intracellular enzymatic antioxidants composed mainly of glutathione peroxidase (GSH-Px), catalase (CAT), superoxide dismutase (SOD) and glutathione reductase counterbalance oxidative stress. Diminished activity of this system may lead to accelerated progression of atherosclerosis. The aim of this study was to assess the activity of CAT, GSH-Px, SOD and glutathione reductase in children with a family history of premature CHD who did not present any other major risk factors of CHD (diabetes, obesity, dyslipidaemia or hypertension). Twenty-two healthy children from high-risk families, selected according to the National Cholesterol Education Program definition, were enrolled in the study. The control group comprised 18 children without a family history of CHD. All the children were healthy and had been screened for hyperlipidaemia, diabetes, hypertension and obesity prior to the study. The erythrocyte activity of CAT, GSH-Px, SOD and glutathione reductase was assessed. Children at high risk of CHD had a statistically significant lower level of GSH-Px and CAT activity than the children in the control group. There were no statistically significant differences in the activity of SOD and glutathione reductase.

Adolescent↗

[GP IIb/IIIa receptor antagonists--molecular and clinical aspects].

Recently many investigators have found that platelet glycoprotein GP IIb/IIIa is responsible for platelet aggregation and plays a pivotal role in acute coronary thrombosis. Thus, GP IIb/IIIa antagonists may play an important role by inhibiting platelet aggregation and their binding to fibrinogen. Drugs that antagonize this binding have been developed for the treatment of thrombotic diseases and acute coronary syndrome. Now, there are three groups of platelet receptor antagonists: monoclonal antibodies, synthetic peptides and non-peptide antagonists. As a result of large clinical trials the potency of those compounds in preventing of coronary thrombosis have been demonstrated. In this article molecular aspects of GP antagonists action and selected clinical trials have been presented.

Animals↗

[Mast cells and atherosclerosis].

Recent data indicate an important role of mast cell in the pathogenesis of atherosclerosis; especially the influence of biologically active substances derived from mast cells such as serine proteinases on metabolism of angiotensin, bradykinin and lipoproteins. The presence of mastocytes in the hinge region of atherosclerotic plaque seems to indicate their important role in plaque rupture and complications of fibrous plaque. Besides the many pathogenic effects of mastocytes they may participate in the maintenance of vascular wall integrity and regeneration. This article presents important aspects of the role of mast cells in pathogenesis of atherosclerosis.

Angiotensins↗

Fibronectin gene polymorphism in patients with lung cancer.

Fibronectin (FN) is a glycoprotein component of connective tissue. It is involved in cancer progression. FN plays a role in non-neoplasmatic lung pathology in which fibronectin gene polymorphisms (RFLPs) have been studied. The aim of our work was to evaluate the frequency of two of fibronectin RFLPs: genotypes AB, AA, BB (HaeIII) and CD, CC, DD (MspI) in patients with lung cancer. The studied group consisted of 63 patients with squamous cell lung cancer and 53 controls without any malignant or proliferative disease. There were no statistically significant differences in the distribution of studied genotypes between lung cancer patients and controls.

Carcinoma, Squamous Cell↗